ZyVersa Therapeutics Inc (ZVSA)
3.53
-0.08
(-2.28%)
USD |
NASDAQ |
Jul 02, 16:00
3.55
+0.02
(+0.57%)
After-Hours: 07:09
ZyVersa Therapeutics Enterprise Value: 0.9136M for July 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| July 02, 2024 | 0.9136M |
| July 01, 2024 | 0.9823M |
| June 28, 2024 | 1.106M |
| June 27, 2024 | 0.9888M |
| June 26, 2024 | 1.089M |
| June 25, 2024 | 0.9303M |
| June 24, 2024 | 1.122M |
| June 21, 2024 | 1.323M |
| June 20, 2024 | 1.999M |
| June 18, 2024 | 2.183M |
| June 17, 2024 | 2.350M |
| June 14, 2024 | 2.350M |
| June 13, 2024 | 2.040M |
| June 12, 2024 | 1.949M |
| June 11, 2024 | 1.730M |
| June 10, 2024 | 1.832M |
| June 07, 2024 | 1.648M |
| June 06, 2024 | 1.932M |
| June 05, 2024 | 2.057M |
| June 04, 2024 | 1.899M |
| June 03, 2024 | 2.024M |
| May 31, 2024 | 2.091M |
| May 30, 2024 | 1.373M |
| May 29, 2024 | 1.528M |
| May 28, 2024 | 1.518M |
| Date | Value |
|---|---|
| May 24, 2024 | 1.565M |
| May 23, 2024 | 1.548M |
| May 22, 2024 | 1.648M |
| May 21, 2024 | 1.64M |
| May 20, 2024 | 1.473M |
| May 17, 2024 | 1.713M |
| May 16, 2024 | 2.024M |
| May 15, 2024 | 2.091M |
| May 14, 2024 | 2.383M |
| May 13, 2024 | 2.525M |
| May 10, 2024 | 2.450M |
| May 09, 2024 | 2.375M |
| May 08, 2024 | 2.642M |
| May 07, 2024 | 3.368M |
| May 06, 2024 | 3.301M |
| May 03, 2024 | 2.517M |
| May 02, 2024 | 2.759M |
| May 01, 2024 | 2.341M |
| April 30, 2024 | 2.383M |
| April 29, 2024 | 2.784M |
| April 26, 2024 | 2.133M |
| April 25, 2024 | 3.038M |
| April 24, 2024 | 3.059M |
| April 23, 2024 | 2.664M |
| April 22, 2024 | 2.765M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-0.9091M
Minimum
Jan 19 2024
71.35M
Maximum
Dec 13 2022
6.216M
Average
4.107M
Median
Oct 05 2023
Enterprise Value Benchmarks
| OptiNose Inc | 196.57M |
| NovaBay Pharmaceuticals Inc | 3.015M |
| Palatin Technologies Inc | 20.32M |
| iBio Inc | 25.20M |
| Theriva Biologics Inc | -11.33M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.827M |
| Total Expenses (Quarterly) | 2.827M |
| EPS Diluted (Quarterly) | -4.53 |
| Earnings Yield | -49.94K% |